Heart Failure Clinical Trial
Nutritional and Functional Changes in Heart Failure and COPD
Summary
Weight loss commonly occurs in patients with chronic heart failure (CHF) and chronic obstructive pulmonary disorder (COPD), negatively influencing their quality of life, treatment response and survival. Loss of muscle protein is generally a central component of weight loss in CHF and COPD patients but patients also have reductions in fat mass and bone density, independent of the severity of the disease state. The purpose of this cross-sectional study is to provide detailed insight in disease related gut function by obtaining information on gut permeability, digestion and absorption of glucose, fat and protein in CHF and COPD patients compared to matched healthy controls. This will provide required information that is necessary to implement new strategies to develop optimal nutritional regimen in CHF and COPD. The hypothesis is that CHF and COPD are related to decreased gut function and absorption, leading to decreased anabolic response. Second, this decreased nutritional status is linked to reduced muscle functioning and possibly decreased cognition. In addition, we will examine the effect of aging on by comparing gut function digestion and absorption of the CHF and COPD aged matched healthy controls to a group of young healthy subjects.
Full Description
This study involves one test day of approximately 7-8 hours. On this test day subjects will ingest a sugar drink to assess gut permeability and gut function, and a protein meal to measure digestion/absorption and the anabolic response to food intake. Subjects will also receive a mixture of amino acids that are made a little heavier than normal, called stable isotopes. This stable isotopes is used to investigate protein behavior in the body (protein kinetics). Blood (100-120 ml in total) and urine samples will be collected over 7 hours.
Eligibility Criteria
Inclusion criteria CHF subjects:
Ability to walk, sit down and stand up independently
Age 45 years or older
Ability to lie in supine or elevated position for 7 hours
Diagnosis of Chronic Heart Failure; under regular care by cardiologist
NYHA class II-IV
Reduced ejection fraction (<45%) assessed in the past 2 years
Clinically stable condition; no hospitalization 4 weeks preceding first study day
Willingness and ability to comply with the protocol
Inclusion criteria COPD subjects:
Ability to walk, sit down and stand up independently
Age 45 years or older
Ability to lie in supine or elevated position for 8 hours
Diagnosis of moderate to very severe chronic airflow limitation and compliant to the following criteria: FEV1 < 70% of reference FEV1
Clinically stable condition and not suffering from a respiratory tract infection or exacerbation of their disease (defined as a combination of increased cough, sputum purulence, shortness of breath, systemic symptoms such as fever, and a decrease in FEV1 > 10% compared with values when clinically stable in the preceding year) at least 4 weeks prior to the first test day
Shortness of breath on exertion
Willingness and ability to comply with the protocol
Inclusion criteria healthy control subjects:
Healthy male or female according to the investigator's or appointed staff's judgment
Ability to walk, sit down and stand up independently
Age 45 years or older (older control group)
Age between 20-30 years old (young group)
Ability to lay in supine or elevated position for 7 hours
No diagnosis of CHF
Willingness and ability to comply with the protocol
Exclusion Criteria:
Any condition that may interfere with the definition 'healthy subject' according to the investigator's judgment (healthy subjects only)
History of untreated metabolic diseases including hepatic or renal disorder
Presence of acute illness or metabolically unstable chronic illness
Presence of fever within the last 3 days
Body mass index >40 kg/m2 (healthy subjects only)
Any other condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient
Use of protein or amino acid containing nutritional supplements within 5 days of first study day
Current use of long-term oral corticosteroids (CHF only)
Use of short course of oral corticosteroids within 4 weeks preceding first study day
Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements
(Possible) pregnancy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
College Station Texas, 77843, United States
How clear is this clinincal trial information?